Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Analysts downgraded XENE, NFLX and MGA, while raising price targets for OCS, INSW, ABEO and STNG.
Stocks · News reference
Ultragenyx Pharmaceutical Says FDA Grants Standard Full Approval Of FAYUVI For Treatment Of Pediatric Patients With Mucopolysaccharidosis Type IIIA
FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week
Abeona Therapeutics had a busy week with treatment network expansion, an FDA approval tied to a licensed therapy and fresh analyst coverage.
Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30
Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and raises the price target from $28 to $30.
Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest
FDA approves Ultragenyx's Fayuvi for Sanfilippo syndrome Type A. Review commercial plans, $3.95 million pricing.
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $39
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $37 to $39.
Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $39
Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $33 to $39.